糖尿病黄斑浮腫の市場規模：治療タイプ別、用途別、エンドユーザー別 - 地域的展望・競合戦略・セグメント予測 (～2033年)

世界の糖尿病黄斑浮腫の市場規模は、2033年にかけて4.69％のCAGRで推移し、152億5,000万米ドルの規模に成長すると予測されています。

糖尿病性視力低下の主な原因の1つは、糖尿病黄斑浮腫 (DME) です。DMEは網膜血管系の透過性亢進によって引き起こされると考えられています。黄斑浮腫と糖尿病網膜症の重症度は関連しています。糖尿病黄斑浮腫の病態生理と発症の背後にある分子機構は複雑であるため、この疾患の分子経路と病態をより深く理解する必要があります。

当レポートでは、世界の糖尿病黄斑浮腫の市場を調査し、市場概要、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

• 促進要因・抑制・機会・課題の分析
• COVID-19による市場への影響

第5章 市場変数と見通し

• SWOT分析
• PESTEL分析
• ポーターのファイブフォース分析
• ヒートマップ分析

第6章 競合情勢

• 製造拠点の分布・販売エリア・製品タイプ
• M&A・提携・製品発売・協力

第7章 世界の糖尿病黄斑浮腫市場：治療タイプ別

• 世界の市場規模のシェア・予測
• 薬物治療
• レーザー治療

第8章 世界の糖尿病黄斑浮腫市場：用途別

• 世界の市場規模のシェア・予測
• 黄斑浮腫
• 黄斑変性症

第9章 世界の糖尿病黄斑浮腫市場：エンドユーザー別

• 世界の市場規模のシェア・予測
• 病院
• クリニック
• その他

第10章 世界の糖尿病黄斑浮腫市場の予測

• 市場規模・市場シェア

第11章 世界の糖尿病黄斑浮腫市場：治療タイプ別

• 市場規模・市場シェアの推移・予測

第12章 世界の糖尿病黄斑浮腫市場：用途別

• 市場規模・市場シェアの推移・予測

第13章 世界の糖尿病黄斑浮腫市場：エンドユーザー別

• 市場規模・市場シェアの推移・予測

第14章 世界の糖尿病黄斑浮腫市場：地域別

• 市場規模・市場シェアの推移・予測
• アジア太平洋
• 欧州
• 中東・アフリカ
• 北米
• ラテンアメリカ

第15章 企業プロファイル

• Alimera Sciences Inc.
• Abbvie Inc.
• Bayer AG
• Bausch Health Companies Inc.
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline Plc
• Kubota Pharmaceutical Hodlings Co. Ltd.
• Novartis AG
• Regen X Bio Inc.
• Regeneron Pharmaceuticals Inc.
• その他

第16章 略語一覧

第17章 参考リンク

第18章 総論

第19章 調査範囲

Diabetic Macular Edema Market Introduction and Overview

According to SPER market research, 'Diabetic Macular Edema Market Size- By Treatment Type, By Application, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Diabetic Macular Edema Market is predicted to reach USD 15.25 billion by 2033 with a CAGR of 4.69%.

One of the most frequent reasons of diabetic vision loss is diabetes-related macular edema (DME). It is believed to be brought on by the hyper permeability of the retinal vasculature. Macular edema and the severity of diabetic retinopathy are related. Due to the complexity of the pathophysiology and molecular mechanisms behind the development of diabetic macular edema, a deeper understanding of the disease's molecular pathways and pathogenesis is required.

The COVID-19 virus first surfaced in December 2019 and has since spread to nearly every country in the world, prompting the World Health Organisation (WHO) to declare a public health emergency. The global healthcare system has been badly disrupted in the aftermath of the coronavirus pandemic due to the financial crisis and the delay in delivering specialist healthcare while prioritising COVID-19 treatments.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Treatment Type, By Application, By End User

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Abbvie Inc., Alimera Sciences Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Kubota Pharmaceutical,Hodlings Co. Ltd., Novartis AG, Regen X Bio Inc., Regeneron Pharmaceuticals Inc.,

Global Diabetic Macular Edema Market Segmentation:

By Treatment Type: Based on the Treatment Type, Global Diabetic Macular Edema Market is segmented as; Drug Therapy and Laser Treatment.

By Application: Based on the Application, Global Diabetic Macular Edema Market is segmented as; Macular Edema and Macular Degeneration.

By End User: Based on the End User, Global Diabetic Macular Edema Market is segmented as; Hospital, Clinics and Other.

Table of Contents

1. Introduction

• 1.1. Scope of the report
• 1.2. Market segment analysis

2. Research Methodology

• 2.1. Research data source
  • 2.1.1. Secondary Data
  • 2.1.2. Primary Data
  • 2.1.3. SPER's internal database
  • 2.1.4. Premium insight from KOL's
• 2.2. Market size estimation
  • 2.2.1. Top-down and Bottom-up approach
• 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

• 4.1. Driver, Restraint, Opportunity and Challenges analysis
  • 4.1.1. Drivers
  • 4.1.2. Restraints
  • 4.1.3. Opportunities
  • 4.1.4. Challenges
• 4.2. COVID-19 Impacts of the Global Diabetic Macular Edema Market

5. Market variable and outlook

• 5.1. SWOT Analysis
  • 5.1.1. Strengths
  • 5.1.2. Weaknesses
  • 5.1.3. Opportunities
  • 5.1.4. Threats
• 5.2. PESTEL Analysis
  • 5.2.1. Political Landscape
  • 5.2.2. Economic Landscape
  • 5.2.3. Social Landscape
  • 5.2.4. Technological Landscape
  • 5.2.5. Environmental Landscape
  • 5.2.6. Legal Landscape
• 5.3. PORTER's Five Forces
  • 5.3.1. Bargaining power of suppliers
  • 5.3.2. Bargaining power of buyers
  • 5.3.3. Threat of Substitute
  • 5.3.4. Threat of new entrant
  • 5.3.5. Competitive rivalry
• 5.4. Heat Map Analysis

6. Competitive Landscape

• 6.1. Global Diabetic Macular Edema Market Manufacturing Base Distribution, Sales Area, Product Type
• 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Diabetic Macular Edema Market

7. Global Diabetic Macular Edema Market, By Treatment Type (USD Million)

• 7.1. Global Diabetic Macular Edema Market Value Share and Forecast, By Treatment Type, 2024-2033
• 7.2. Drug Therapy
• 7.3. Laser Treatment

8. Global Diabetic Macular Edema Market, By Application (USD Million)

• 8.1. Global Diabetic Macular Edema Market Value Share and Forecast, By Application, 2024-2033
• 8.2. Macular Edema
• 8.3. Macular Degeneration

9. Global Diabetic Macular Edema Market, By End User (USD Million)

• 9.1. Global Diabetic Macular Edema Market Value Share and Forecast, By End User, 2024-2033
• 9.2. Hospital
• 9.3. Clinics
• 9.4. Others

10. Global Diabetic Macular Edema Market Forecast, 2020-2033 (USD Million)

• 10.1. Global Diabetic Macular Edema Market Size and Market Share

11. Global Diabetic Macular Edema Market, By Treatment Type 2020-2033 (USD Million)

• 11.1. Global Diabetic Macular Edema Market Size and Market Share By Treatment Type (2020-2026)
• 11.2. Global Diabetic Macular Edema Market Size and Market Share By Treatment Type (2027-2033)

12. Global Diabetic Macular Edema Market, By Application, 2020-2033 (USD Million)

• 12.1. Global Diabetic Macular Edema Market Size and Market Share By Application (2020-2026)
• 12.2. Global Diabetic Macular Edema Market Size and Market Share By Application (2027-2033)

13. Global Diabetic Macular Edema Market, By End User, 2019-2033 (USD Million)

• 13.1. Global Diabetic Macular Edema Market Size and Market Share By End User (2020-2026)
• 13.2. Global Diabetic Macular Edema Market Size and Market Share By End User (2027-2033)

14. Global Diabetic Macular Edema Market, By Region, 2019-2033 (USD Million)

• 14.1. Global Diabetic Macular Edema Market Size and Market Share By Region (2020-2026)
• 14.2. Global Diabetic Macular Edema Market Size and Market Share By Region (2027-2033)
• 14.3. Asia-Pacific
  • 14.3.1. Australia
  • 14.3.2. China
  • 14.3.3. India
  • 14.3.4. Japan
  • 14.3.5. South Korea
  • 14.3.6. Rest of Asia-Pacific
• 14.4. Europe
  • 14.4.1. France
  • 14.4.2. Germany
  • 14.4.3. Italy
  • 14.4.4. Spain
  • 14.4.5. United Kingdom
  • 14.4.6. Rest of Europe
• 14.5. Middle East and Africa
  • 14.5.1. Kingdom of Saudi Arabia
  • 14.5.2. United Arab Emirates
  • 14.5.3. Rest of Middle East & Africa
• 14.6. North America
  • 14.6.1. Canada
  • 14.6.2. Mexico
  • 14.6.3. United States
• 14.7. Latin America
  • 14.7.1. Argentina
  • 14.7.2. Brazil
  • 14.7.3. Rest of Latin America

15. Company Profile

• 15.1. Alimera Sciences Inc.
  • 15.1.1. Company details
  • 15.1.2. Financial outlook
  • 15.1.3. Product summary
  • 15.1.4. Recent developments
• 15.2. Abbvie Inc.
  • 15.2.1. Company details
  • 15.2.2. Financial outlook
  • 15.2.3. Product summary
  • 15.2.4. Recent developments
• 15.3. Bayer AG
  • 15.3.1. Company details
  • 15.3.2. Financial outlook
  • 15.3.3. Product summary
  • 15.3.4. Recent developments
• 15.4. Bausch Health Companies Inc.
  • 15.4.1. Company details
  • 15.4.2. Financial outlook
  • 15.4.3. Product summary
  • 15.4.4. Recent developments
• 15.5. F. Hoffmann-La Roche Ltd
  • 15.5.1. Company details
  • 15.5.2. Financial outlook
  • 15.5.3. Product summary
  • 15.5.4. Recent developments
• 15.6. GlaxoSmithKline Plc
  • 15.6.1. Company details
  • 15.6.2. Financial outlook
  • 15.6.3. Product summary
  • 15.6.4. Recent developments
• 15.7. Kubota Pharmaceutical Hodlings Co. Ltd.
  • 15.7.1. Company details
  • 15.7.2. Financial outlook
  • 15.7.3. Product summary
  • 15.7.4. Recent developments
• 15.8. Novartis AG
  • 15.8.1. Company details
  • 15.8.2. Financial outlook
  • 15.8.3. Product summary
  • 15.8.4. Recent developments
• 15.9. Regen X Bio Inc.
  • 15.9.1. Company details
  • 15.9.2. Financial outlook
  • 15.9.3. Product summary
  • 15.9.4. Recent developments
• 15.10. Regeneron Pharmaceuticals Inc.
  • 15.10.1. Company details
  • 15.10.2. Financial outlook
  • 15.10.3. Product summary
  • 15.10.4. Recent developments
• 15.11. Others

16. List of Abbreviations

17. Reference Links

18. Conclusion

19. Research Scope